Oxford BioMedica : Directors Dealings / Market Share Purchases

Directors Dealings / Market Share Purchases

Oxford, UK - 16 September 2019: Oxford Biomedica plc ('Oxford Biomedica' or 'the Group') (LSE: OXB), a leading gene and cell therapy group, today announces that Dr. Andrew Heath, Deputy Chairman and Senior Independent Director of the Group, and Natalie Walter, the General Counsel of the Group, have both increased their shareholdings in the Company through the purchase of shares.

Dr. Heath, Deputy Chairman and Senior Independent Director of the Group has purchased 2,000 ordinary shares of 50p each ('Ordinary Shares') in the Company on 13 September 2019 on the London Stock Exchange at a price of 556.0p and additionally 3,000 ordinary shares of 50p each in the Company on 13 September 2019 on the London Stock Exchange at a price of 567.8p. Following this purchase Dr. Heath holds 55,000 shares representing 0.07% of the Company.

Natalie Walter, General Counsel of the Group, has purchased 1,754 Ordinary Shares in the Company on 13 September 2019 on the London Stock Exchange at a price of 566.6p. Following this purchase Natalie Walter holds 1,754 shares representing 0.002% of the Company.

The below notification, made in accordance with the requirements of the EU Market Abuse Regulation, gives further detail of the number of Ordinary Shares purchased.

1.	Details of the person discharging material responsibilities/person closely associated
a.	Name	Andrew Heath
2.	Reason for the notification
a.	Position/status	Deputy Chairman and Senior Independent Director
b.	Initial notification /amendment	Initial notification
3.	Details of the issuer, emission allowance, market participant, auction platform, auctioneer or auction monitor
a.	Name	Oxford Biomedica plc
b.	Legal Entity Identifier	213800S1GVQNXQ15K851
4.	Details of the transaction(s); section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a.	Description of the financial instrument, type of instrument identification code	Oxford Biomedica plc Ordinary Shares of 50p each GB00BDFBVT43
b.	Nature of the transaction	Purchaseof ordinary shares
c.	Currency	GBP - British Pound
d.	Price(s) and volume(s)	Price(s)	Volume(s)
		£5.56	2,000
		£5.68	3,000
e.	Aggregated information · Aggregated volume · Price · Aggregated total	5,000 £5.631 £28,154.30
f.	Date of the transaction	2019-09-13
g.	Place of the transaction	London Stock Exchange, Main Market (XLON)

1.	Details of the person discharging material responsibilities/person closely associated
a.	Name	Natalie Walter
2.	Reason for the notification
a.	Position/status	General Counsel
b.	Initial notification /amendment	Initial notification
3.	Details of the issuer, emission allowance, market participant, auction platform, auctioneer or auction monitor
a.	Name	Oxford Biomedica plc
b.	Legal Entity Identifier	213800S1GVQNXQ15K851
4.	Details of the transaction(s); section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a.	Description of the financial instrument, type of instrument identification code	Oxford Biomedica plc Ordinary Shares of 50p each GB00BDFBVT43
b.	Nature of the transaction	Purchaseof ordinary shares
c.	Currency	GBP - British Pound
d.	Price(s) and volume(s)	Price(s)	Volume(s)
		£5.67	1,754
e.	Aggregated information · Aggregated volume · Price · Aggregated total	1,754 £5.6658 £9,937.81
f.	Date of the transaction	2019-09-13
g.	Place of the transaction	London Stock Exchange, Main Market (XLON)

The issued share capital of the Group is 76,767,971 ordinary 50p shares.

-Ends-

For further information, please contact:
Oxford Biomedica plc: Natalie Walter, Company Secretary	Tel: [phone]

About Oxford Biomedica

Oxford Biomedica (LSE:OXB) is a leading gene and cell therapy group focused on developing life changing treatments for serious diseases. Oxford Biomedica and its subsidiaries (the 'Group') have built a sector leading lentiviral vector delivery platform (LentiVector^®), which the Group leverages to develop in vivo and ex vivo products both in-house and with partners. The Group has created a valuable proprietary portfolio of gene and cell therapy product candidates in the areas of oncology, ophthalmology and CNS disorders. The Group has also entered into a number of partnerships, including with Novartis, Sanofi, Axovant Gene Therapies, Orchard Therapeutics, Santen, Boehringer Ingelheim, the UK Cystic Fibrosis Gene Therapy Consortium and Imperial Innovations, through which it has long-term economic interests in other potential gene and cell therapy products. Oxford Biomedica is based across several locations in Oxfordshire, UK and employs more than 480 people. Further information is available atwww.oxb.com